-
Aditxt Webinar at 2pm ET to Explore PRESECO Results
Aditxt Webinar at 2pm ET to Explore PRESECO Results
Share
RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc. (“Aditxt”) (Nasdaq: ADTX), has announced a webinar at 2pm ET this afternoon to discuss its earlier announcement today.
All investors are invited to attend, whether professional or individual.
On today’s webinar, CEO Amro Albanna will be sharing full information with all existing and potential investors. If you have questions, please submit them via email: aditxt@edisongroup.com.
To join the webinar, click here at 2pm. Or paste the link directly into your browser: https://us06web.zoom.us/j/82136059143
Contacts
Aditxt, Inc.
IR@aditxt.com
Media and Investor Relations Contact:
Edison Investment Research
aditxt@edisongroup.com
More News From Aditxt, Inc.
Dana-Farber Cancer Institute Study Demonstrates Predictive Value of Ignite Proteomics’ RPPA Platform for T-DXd (Enhertu®) Therapy in Metastatic Breast Cancer Patients
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, today announced that its precision oncology subsidiary, Ignite Proteomics, LLC (“Ignite” or “Ignite Proteomics”), has been featured in a peer-reviewed study published online ahead of print in npj Precision Oncology, a Nature journal. The study, led by investigators at Dana-Farber Cancer Institute, evaluated outcomes among patien...
Aditxt Subsidiary Ignite Proteomics Appoints Public Company Veteran Jeff Busch as Chief Executive Officer
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, today announced the appointment of Jeff Busch as Chief Executive Officer of its subsidiary, Ignite Proteomics, LLC (“Ignite” or “Ignite Proteomics”). Ignite Proteomics was recently acquired by Aditxt and operates a commercial-stage precision oncology platform designed to guide cancer therapy selection through functional protein...
Aditxt Acquires Ignite Proteomics to Address a Critical Challenge in Cancer Care: Optimizing Therapy Selection
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, today announced the acquisition of Ignite Proteomics, LLC (“Ignite”), a commercial-stage precision oncology company focused on addressing a critical challenge in cancer care: optimizing therapy selection. Ignite’s functional proteomics platform has demonstrated the ability to identify cancer therapy responses that may not be cap...